Skip to content Skip to sidebar Skip to footer

Newsletter

Healthcare Stocks

Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!

What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful story? It would have been possible believe back in those days, but it was still far from certain it would be the case. The recent example of Opthea shows biotech is a risky business and…

ByNick SundichApril 24, 2025

Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591

Neuren Pharmaceuticals (ASX:NEU) is an ASX biotech company that has had a stellar past few years, but it is now facing the question: 'Where to now?' Companies with just one asset targeting one indication in just one jurisdiction can only go so far, and that is the step Neuren is at with Trofinetide. Its true that…

ByNick SundichApril 15, 2025

CSL (ASX:CSL): Its promised double-digit earnings growth for the rest of the 2020s, but will Trump’s tariffs shatter the dream?

CSL has been hit more than most other stocks due to Trump tariffs. While many companies being sold off merely 'could' be impacted, this company almost certainly will be impacted. And if it is, the company's promise of 'double-digit earnings growth' for the rest of the decade might not be kept. CSL is the ASX's largest…

ByNick SundichApril 14, 2025

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in Australia, New Zealand and Singapore, plus approval is pending in Canada and Thailand. But the US was the biggest piece of the US$3.5bn pie that is the company's global addressable market, and now it is…

ByNick SundichApril 4, 2025

The Australian Federal Budget 2025: Which Sectors Will Win and Which Will Lose?

The 2025 Federal Budget has been released, sparking conversations across boardrooms, households, and political circles. Described as a "budget for uncertain times," Treasurer Jim Chalmers has carefully balanced offering cost-of-living relief, strengthening national security, and managing inflation pressures. But who are the real winners and losers? This year’s budget demonstrates Canberra's commitment to energy transition, housing…

ByUjjwal MaheshwariMarch 28, 2025

Should you use your tax cut to invest in stocks? And how should you go about it?

Should you use your tax cut to invest in stocks? With another unexpected round of tax cuts starting from the middle of next year, unveiled in the federal budget earlier this week, this is a question facing many. This round isn't that large - only $536 a year and little over $10 a week by…

ByNick SundichMarch 27, 2025

Opthea (ASX:OPT): It’s a tragedy to see the dream is (most likely) over after poor Phase 3 data

It has been a few years since investors have paid attention to biotech Opthea (ASX:OPT) on the scale that they have in the past week or so. Since its stellar Phase 2 trial results in 2019, it has toiled away at a Phase 3 trial. Well, the company finally got the results back and it…

ByNick SundichMarch 27, 2025

Truscreen (ASX:TRU): Taking a radical path to wide-spread commercialisation

Truscreen (ASX:TRU) is not taking the conventional path ASX medtech stocks take to market. Typically they seek approval in the US and then use that to set up shop across the world. Truscreen is instead starting its journey in Low-to-Middle Income Countries (LMICs). And even though shareholders may not realise it, this may actually be…

ByNick SundichMarch 12, 2025

Healthcare Stocks on the Rise: Capitalising on Medicare Reforms

Are you looking to take advantage of the growing opportunities in the healthcare sector? Markets are once again focusing on healthcare stocks following recent pledges by politicians to expand Medicare funding in Australia. The Australian government and opposition have unveiled substantial plans to improve access to healthcare services for all Australians. These reforms promise that bulk-billed…

ByUjjwal MaheshwariFebruary 27, 2025

Atomo Diagnostics (ASX:AT1): Not just another Rapid Diagnostic (RDT) company

Atomo Diagnostics (ASX:AT1) may be written off by some investors just because it is a rapid test kit company. Yes, we know rapid COVID tests were a booming market during the pandemic, but demand is well off all time highs - and indeed, the company no longer performs COVID testing. But there was, is and…

ByNick SundichFebruary 26, 2025

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!

Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591

CSL (ASX:CSL): Its promised double-digit earnings growth for the rest of the 2020s, but will Trump’s tariffs shatter the dream?

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

The Australian Federal Budget 2025: Which Sectors Will Win and Which Will Lose?

Should you use your tax cut to invest in stocks? And how should you go about it?

Opthea (ASX:OPT): It’s a tragedy to see the dream is (most likely) over after poor Phase 3 data

Truscreen (ASX:TRU): Taking a radical path to wide-spread commercialisation

Healthcare Stocks on the Rise: Capitalising on Medicare Reforms

Atomo Diagnostics (ASX:AT1): Not just another Rapid Diagnostic (RDT) company

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here